Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
What is your approach to the management of treatment-related MDS?
What are some of the prognostic factors that you look into compared with de-novo MDS?
Related Questions
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
Does treating CLL reduce the risk of non-melanoma skin cancers?
Do you routinely include bone marrow examination in your initial evaluation of a patient with chronic myeloid leukemia?
How would you manage a patient with polycythemia and MPN symptoms (aquagenic pruritus, fatigue) that is JAK2/CALR/MPL negative but peripheral blood NGS positive for IDH2?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
How do you monitor and manage minimal residual disease (MRD) in patients with core-binding factor (CBF) AML who are in remission post-induction and consolidation therapy?
How do you approach neutropenia in patients being treated with obinutuzumab/venetoclax for CLL?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
In treatment naive CLL without del(17p)/TP53, will the recent interim analysis of fixed duration acalabrutinib plus venetoclax +/- obinutuzumab vs chemoimmunotherapy in the AMPLIFY trial change your practice?